Medicus Pharma Ltd (NASDAQ:MDCX) Short Interest Update

Medicus Pharma Ltd (NASDAQ:MDCX) was the target of a large decline in short interest in June. As of June 15th, there was short interest totaling 1,928,591 shares, a decline of 35.4% from the May 31st total of 2,984,551 shares. Approximately 3.7% of the shares of the stock are short sold. Based on an average trading volume of 1,878,019 shares, the days-to-cover ratio is presently 1.0 days.

Medicus Pharma Stock Performance

Shares of NASDAQ MDCX remained flat at $0.42 during trading on Friday. 923,426 shares of the company’s stock were exchanged, compared to its average volume of 1,899,073. Medicus Pharma has a one year low of $0.25 and a one year high of $3.69. The business’s 50 day moving average is $0.35 and its 200 day moving average is $0.79. The stock has a market cap of $23.59 million, a PE ratio of -0.16 and a beta of -0.05.

Medicus Pharma (NASDAQ:MDCX) last released its quarterly earnings results on Thursday, May 14th. The company reported ($0.31) EPS for the quarter, missing the consensus estimate of ($0.18) by ($0.13). As a group, equities analysts expect that Medicus Pharma will post -0.51 EPS for the current year.

Analyst Upgrades and Downgrades

A number of equities research analysts recently weighed in on MDCX shares. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Medicus Pharma in a report on Friday, April 10th. Roth Mkm began coverage on Medicus Pharma in a report on Tuesday, April 21st. They set a “buy” rating on the stock. Finally, D. Boral Capital restated a “buy” rating and issued a $9.00 target price on shares of Medicus Pharma in a research note on Monday, April 20th. Two research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average target price of $9.00.

Institutional Investors Weigh In On Medicus Pharma

Several hedge funds and other institutional investors have recently made changes to their positions in MDCX. Armistice Capital LLC bought a new stake in shares of Medicus Pharma during the fourth quarter worth $2,771,000. Private Advisor Group LLC increased its position in Medicus Pharma by 36.8% in the first quarter. Private Advisor Group LLC now owns 240,055 shares of the company’s stock worth $110,000 after purchasing an additional 64,560 shares during the period. Yorkville Advisors Global LP bought a new stake in Medicus Pharma during the 3rd quarter worth about $532,000. Jane Street Group LLC bought a new stake in Medicus Pharma during the 4th quarter worth about $92,000. Finally, Wilmington Savings Fund Society FSB raised its holdings in Medicus Pharma by 100.0% during the 4th quarter. Wilmington Savings Fund Society FSB now owns 51,244 shares of the company’s stock worth $78,000 after purchasing an additional 25,622 shares during the last quarter.

About Medicus Pharma

Medicus Pharma, Inc, traded on the Nasdaq under the ticker MDCX, is a specialty pharmaceutical company focused on the development, acquisition and commercialization of prescription therapies. The company’s core business centers on oncology supportive care and critical care products, with its lead offering being Levoleucovorin injection, an FDA-approved agent designed to reduce toxicity and enhance efficacy of certain chemotherapeutic regimens in colorectal cancer.

Headquartered in the United States, Medicus Pharma has built its portfolio through strategic licensing and acquisition of sterile injectable and oral therapies.